Company profile
Ceryvyn Therapeutics
- Industry
- Biotechnology Research
- Employees
- 17
- Headquarters
- Hawthorn East, Victoria
- LinkedIn followers
- 7,387
- Office locations
- 1
Ceryvyn Therapeutics company summary
Ceryvyn Therapeutics is a company in the Biotechnology Research industry, headquartered in Hawthorn East, Victoria. On LinkedIn the company has around 17 employees and 7,387 followers. Its listed specialties include Women's health, Clinical development, Respiratory disease, Rare disease, Biopharma.
What technology does Ceryvyn Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Ceryvyn Therapeutics
Ceryvyn Therapeutics Ltd (ASX: CYV) is a clinical-stage biopharmaceutical company developing innovative therapies by translating advances in human biology into transformative medicines for patients with serious diseases. The Company seeks to identify biological mechanisms that drive disease and develop targeted therapies capable of addressing significant unmet medical need. Ceryvyn’s initial focus is lymphangioleiomyomatosis (LAM), a rare, chronic and progressive systemic disease that predominantly affects women and primarily involves the lungs, where it leads to progressive loss of lung function. Despite currently available therapies, there remains no cure and significant unmet medical need. The Company’s lead development program, CYV-101, is a first-in-class fusion protein designed to selectively bind and neutralise VEGF-C and VEGF-D, key signalling proteins involved in pathological lymphangiogenesis. By targeting a fundamental biological pathway believed to drive disease progression, CYV-101 has the potential to offer a differentiated therapeutic approach for patients with LAM. Ceryvyn is committed to building a biotechnology company grounded in scientific excellence, rigorous clinical development and a relentless focus on improving the lives of patients while creating sustainable long-term value for shareholders.
Specialties
Where is Ceryvyn Therapeutics located?
Ceryvyn Therapeutics lists 1 location.
Compare companies similar to Ceryvyn Therapeutics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Ceryvyn Therapeutics ceryvyn.com | Biotechnology Research | 17 | - | Hawthorn East, Victoria |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Ceryvyn Therapeutics
What does Ceryvyn Therapeutics do?
Ceryvyn Therapeutics Ltd (ASX: CYV) is a clinical-stage biopharmaceutical company developing innovative therapies by translating advances in human biology into transformative medicines for patients with serious diseases. The Company seeks to identify biological mechanisms that drive disease and develop targeted therapies capable of addressing significant unmet medical need. Ceryvyn’s initial focus is lymphangioleiomyomatosis (LAM), a rare, chronic and progressive systemic disease that predominantly affects women and primarily involves the lungs, where it leads to progressive loss of lung function. Despite currently available therapies, there remains no cure and significant unmet medical need. The Company’s lead development program, CYV-101, is a first-in-class fusion protein designed to selectively bind and neutralise VEGF-C and VEGF-D, key signalling proteins involved in pathological lymphangiogenesis. By targeting a fundamental biological pathway believed to drive disease progression, CYV-101 has the potential to offer a differentiated therapeutic approach for patients with LAM. Ceryvyn is committed to building a biotechnology company grounded in scientific excellence, rigorous clinical development and a relentless focus on improving the lives of patients while creating sustainable long-term value for shareholders.
How many employees does Ceryvyn Therapeutics have?
Ceryvyn Therapeutics has around 17 employees on LinkedIn.
Where is Ceryvyn Therapeutics headquartered?
Ceryvyn Therapeutics is headquartered in Hawthorn East, Victoria.
Build a lead list from companies like Ceryvyn Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.